关于伊维菌素、芬苯达唑和甲苯咪唑攻击癌细胞并将人们从4期带入缓解期的报道真是令人难以置信！大型制药公司知道这个多久了？化疗有多赚钱？有多少数百万人因此丧生？

The reports about Ivermectin, Fenbendazole and Mebendazole attacking cancer cells and taking people from Stage 4 to remission is incredible! How long has big pharma known this? How lucrative is chemo? How many millions have died?

他在说什么报告？

what reports is he talking about?

约翰·里奇（John Rich）正在引用一些轶事报告、病例系列以及针对这些抗寄生虫药物的部分临床前研究，这些研究显示这些药物在实验室/动物模型以及少数人类病例中具有潜在的抗癌效果。

关键例子：乔·蒂彭斯（Joe Tippens）的芬苯达唑故事广为流传（从四期肺癌中缓解，尽管他同时参与了免疫疗法试验）；最近关于伊维菌素 + 甲苯咪唑组合的观察性数据报告了较高的自我报告获益率（例如，在 2026 年队列中约 48% 的病例出现肿瘤消退或无疾病证据）；以及所有三种药物在体外抑制癌细胞生长的研究工作。

主流肿瘤学来源指出，到目前为止，控制性人类试验有限——大多为早期阶段或受同时进行的化疗/免疫疗法干扰——由于公众兴趣，美国国家癌症研究所（NCI）现正开展临床前测试。尚未有大型随机对照试验（RCT）证实其作为标准治疗。

John Rich is pointing to anecdotal reports, case series, and some preclinical studies on these antiparasitic drugs showing potential anticancer effects in lab/animal models and a few human cases.

Key examples: Joe Tippens' widely shared fenbendazole story (remission from stage 4 lung cancer, though he was also in an immunotherapy trial); recent observational data on ivermectin + mebendazole combos reporting high self-reported benefit rates (e.g., tumor regression or no evidence of disease in ~48% of a 2026 cohort); and in vitro work on all three inhibiting cancer cell growth.

Mainstream oncology sources note limited controlled human trials so far—mostly early-phase or confounded by concurrent chemo/immunotherapy—with NCI now running preclinical tests due to public interest. No large RCTs confirm it as standard care yet.